Navigation Links
Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
Date:3/10/2008

DALLAS, March 10 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that its management team has scheduled a conference call for March 13, 2008 at 10:00 a.m. ET to update the financial community about the status of its clinical trial programs as well as its business opportunities.

Interested parties may participate in the call by dialing (877) 407-8293; callers outside the U.S. may participate by dialing (201) 689-8349 about 5-10 minutes prior to 10:00 a.m. ET. The conference call will also be available on replay starting at 12:00 noon ET on March 13, 2008, and ending on April 13, 2008. For the replay, U.S. participants please dial (877) 660-6853 (replay account # 294, replay conference #278416). The access number for the replay for callers outside the U.S. is (201) 612-7415 (replay account # 294, replay conference # 278416).

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM) -- mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additiona
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
2. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
3. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
4. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
5. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
8. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
9. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...., Nov. 19 Amgen,(Nasda...mpany, a subsidiary of,Takeda Pharmaceutical Comp...ollment in the Phase 3 MONET1 trial evaluating mot...nd carboplatin for the first-line treatment of,ad... temporarily suspended,following a planned safety...
(Date:11/19/2008)...Nov. 19 Biotech scientists increas...logy research to better understand the effects of ...s, reports Genetic Engineering & Biotechnolog... figuring out a new compound,s mechanism of action... technique, according to the November 15 issue of ...
(Date:11/18/2008)... NeuroDiscovery Ltd (ASX:...and drug development Company,and Sosei Group Cor...ding,international biopharmaceutical company, tod...ther pivotal pre-clinical efficacy data for NSL-04... therapy for neuropathic pain and has,successfull...
(Date:11/18/2008)... 18 Forty-two leading U...mber national forum to consider cutting-edge innov... national economy from outbreaks of dangerous zoon... , Among those innovations: , , , ...hen table that detects highly contagious and dange...
Breaking Medicine Technology:Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7GEN Reports on the Trend Toward Predictive Toxicogenomics 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2International Aid Named as a MinistryWatch com Shining Light Christian Ministry 8404 1International Aid Named as a MinistryWatch com Shining Light Christian Ministry 8404 2IQS Donates Quality Management Software to Family Health International 8402 1IQS Donates Quality Management Software to Family Health International 8402 2IQS Donates Quality Management Software to Family Health International 8402 3Genome Technology Magazine Names Top Young Investigators of 2007 2246 1Genome Technology Magazine Names Top Young Investigators of 2007 2246 2Robin C Stracey Joins Cantimer Inc as President and CEO 2244 1Robin C Stracey Joins Cantimer Inc as President and CEO 2244 2
...novative technology has enabled more and more labo...ns office, the central laboratory is hardly threat... that medium and large labs are busier than ever b...old standard reliability and ability to handle ver...nd pivotal position in the clinical landscape. ,...
...rus (EBV), which causes infectious mononucleosis (...occurs worldwide, and most people become infected ...d States, as many as 95 percent of adults between ... developed countries, including the U.S., infectio... young adulthood, causing infectious mononucleosis...
Other Medicine Technology:When Volume Matters, Immunoassay Systems Deliver 2When Volume Matters, Immunoassay Systems Deliver 3Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies 2Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies 3
(Date:11/21/2008)...008)The University of Texas Health Science Center ...ellence in Aging Studies (TEXAS), to promote geria...s $2 million award from the Donald W. Reynolds Fou...is will allow us to teach geriatric medicine princ...dent to practicing physicians. With the reach of L...
(Date:11/21/2008)...ain cautious about future antibiotic resistance fr...(HealthDay News) -- People with moderate to severe...be able to reduce the frequency of exacerbations t... a new report says. , The study, published in ...nal of Respiratory and Critical Care Medicine , fo...
(Date:11/21/2008)...21 NursingCenter.com, the premier ...peer reviewed content, has been,updated to improv...tered,users. Powered by Lippincott Williams &...er 900 peer-reviewed continuing education activiti...han 50 leading nursing journals.,Lippincott Willi...
(Date:11/21/2008).... 21 Barr Pharmaceutical...areholders overwhelmingly approved the proposals s...rr by Teva Pharmaceuticals Industries Ltd. (Nasdaq... the overwhelming support of the transaction by th... Chairman and CEO. "We are pleased with the progre...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4
...ncephalopathy (BSE) is the condition in which ther...le. It is very fatal.// The Canadian Food Inspect...he fourth cow was tested positive for this disease...ix-years old. The results of the investigation wer...
...nternational Journal of Cancer on February 17, 200...lon cancer and the level of physical activity in w...erican women has found no such link. Experts felt... the production of prostaglandins and insulin besi...
... organically have better health value. Besides bei... insecticides they increase the nutritional value ...he globe research is being done in this field. P...e harmful chemicals over food surface and cause he...
...rt attack that are commonly referred to as non-com...Indian economy, // claiming approximately $237 of ...es by World Health Organization. While India lost...the toll might reach 60 million due to health rela...
Other Medicine News:Health News:Women, Exercise and Colon Cancer 2
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...e Dual Adaptor allows the surgeon to document proc...eo or 35mm photography. Many different types of ad...
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...ersal Microsurgical Video Adaptor (US pat. no. 5,2...both single-chip and 3CCD cameras on the same adap...
...ALLEGRO Topolyzer and T-CAT have been optimized to...rection and to interact in perfect synchronization...ll necessary treatment and patient parameters are ...GRETTO WAVE laser systems via diskette, mini CD or...
...The WaveScan WaveFront System is an ophthalmic dia...ror and wavefront aberrations of the human eye usi...ents can be used to determine regular (sphero-cyli...rrations) that cause decreased or blurry vision in...
Medicine Products: